Search Results 1021-1030 of 16411 for monoclonal antibody

1. Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy - Mayo Clinic

   Patients who have been treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in any other clinical studies; Pregnant or ...

2. Publications - Madiha Fida, M.B.B.S. - Mayo Clinic

   ... monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. Virus Evol. 2023; 9 (2):veac104 Epub 2022 Nov 05. View PubMed ...

3. CSF1R and TAM receptor inhibition with Q702 - Mayo Clinic

   Participation eligibility · Targeted therapeutics other than monoclonal antibodies (e.g., kinases inhibitors) ≤2 weeks prior to registration. · Monoclonal ...

4. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.

5. A Study to Evaluate Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer - Mayo Clinic

   Within 4 weeks (28 days): systemic cytotoxic chemotherapy; small molecule targeted agents with half-life ≥ 7 days; monoclonal antibodies, antibody-drug ...

6. Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks prior to study Day 1 or who has not recovered from adverse ...

7. Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) - Mayo Clinic

   deoxyribonucleic acid antibody seropositivity or anti-citrullinated protein antibodies-positive rheumatoid arthritis, or SSc mimics (eg, scleromyxedema,

8. Immune globulin (intramuscular route, intravenous route, subcutaneous route) - Mayo Clinic

   Immune globulin contains antibodies that make your immune system stronger. It is used for patients who have primary humoral immunodeficiency (PI) ...

9. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

   Part 2 (Cohort Expansion): Subjects must have received adequate prior therapy including at a minimum including at a minimum anti-CD20 monoclonal antibody ...

10. A Study to Evaluate Effectiveness and Safety of MBG453 in Combination with Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia-2 (CMML-2) - Mayo Clinic

    History of severe hypersensitivity reaction to any ingredients of the study treatments (azacitidine or MBG453) or their excipients, or to monoclonal antibodies.